Related Experiment Video

Updated: Aug 19, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Myeloproliferative disorders

A J Bench1, N C Cross, B J Huntly

  • 1Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2XY, UK.

Best Practice & Research. Clinical Haematology
|October 20, 2001
PubMed

Insights

Myeloproliferative disorders (MPDs) involve abnormal blood cell growth. While lacking a single marker, chromosomal abnormalities in MPDs like polycythaemia vera indicate a poor prognosis.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloproliferative disorders (MPDs) are pre-leukaemic conditions characterized by the overproduction of myeloid lineages.
  • Unlike chronic myeloid leukaemia, MPDs lack a pathognomonic chromosomal abnormality.
  • Chromosomal abnormalities are observed in 30-40% of polycythaemia vera and idiopathic myelofibrosis cases, often correlating with a worse prognosis.

Purpose of the Study:

  • To investigate chromosomal abnormalities in myeloproliferative disorders.
  • To identify potential genetic targets and novel fusion proteins in MPDs.

Main Methods:

  • Analysis of chromosomal abnormalities in patients with polycythaemia vera, idiopathic myelofibrosis, and essential thrombocythaemia.
  • Molecular mapping of specific chromosomal deletions (20q, 13q).
  • Identification of fusion proteins in rare myeloproliferative syndromes.

Main Results:

  • Consistent acquired chromosomal changes in MPDs include del(20q), trisomy 8, trisomy 9, and duplication of 1q.
  • These abnormalities often originate in multipotent progenitor cells.
  • Molecular mapping has identified candidate genes for 20q and 13q deletions, and novel fibroblast growth factor receptor-1 fusion proteins have been identified.

Conclusions:

  • Chromosomal abnormalities are significant in certain MPDs and can predict prognosis.
  • Further research into candidate genes and fusion proteins may reveal new therapeutic targets for MPDs.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Production of Formed Elements01:34

Production of Formed Elements

Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.